Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September Sep 5, 2025
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research Sep 3, 2025
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Aug 27, 2025
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Aug 14, 2025
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 Aug 7, 2025
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option Jul 2, 2025
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) Jun 24, 2025
